Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.

Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N.

Cancers (Basel). 2019 Jul 19;11(7). pii: E1015. doi: 10.3390/cancers11071015.

2.

Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.

Gandellini P, Casiraghi N, Rancati T, Benelli M, Doldi V, Romanel A, Colecchia M, Marenghi C, Valdagni R, Demichelis F, Zaffaroni N.

Eur Urol Oncol. 2019 May;2(3):277-285. doi: 10.1016/j.euo.2018.08.010. Epub 2018 Sep 10.

3.

Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer.

Beretta GL, Zaffaroni N.

Front Chem. 2019 May 28;7:369. doi: 10.3389/fchem.2019.00369. eCollection 2019. Review.

4.

Distinct biological responses of metastatic castration resistant prostate cancer cells upon exposure to G-quadruplex interacting naphthalenediimide derivatives.

Recagni M, Greco ML, Milelli A, Minarini A, Zaffaroni N, Folini M, Sissi C.

Eur J Med Chem. 2019 Sep 1;177:401-413. doi: 10.1016/j.ejmech.2019.05.066. Epub 2019 May 24.

PMID:
31158753
5.

Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.

Lanzi C, Dal Bo L, Favini E, Tortoreto M, Beretta GL, Arrighetti N, Zaffaroni N, Cassinelli G.

Cancers (Basel). 2019 Mar 22;11(3). pii: E408. doi: 10.3390/cancers11030408.

6.

Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.

Spinello A, Martini S, Berti F, Pennati M, Pavlin M, Sgrignani J, Grazioso G, Colombo G, Zaffaroni N, Magistrato A.

Eur J Med Chem. 2019 Apr 15;168:253-262. doi: 10.1016/j.ejmech.2019.02.045. Epub 2019 Feb 13.

PMID:
30822713
7.

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition.

El Bezawy R, Tinelli S, Tortoreto M, Doldi V, Zuco V, Folini M, Stucchi C, Rancati T, Valdagni R, Gandellini P, Zaffaroni N.

J Exp Clin Cancer Res. 2019 Feb 4;38(1):51. doi: 10.1186/s13046-019-1060-z.

8.

LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation.

Profumo V, Forte B, Percio S, Rotundo F, Doldi V, Ferrari E, Fenderico N, Dugo M, Romagnoli D, Benelli M, Valdagni R, Dolfini D, Zaffaroni N, Gandellini P.

Nat Commun. 2019 Jan 18;10(1):307. doi: 10.1038/s41467-018-08153-2.

9.

Role of FoxO Proteins in Cellular Response to Antitumor Agents.

Beretta GL, Corno C, Zaffaroni N, Perego P.

Cancers (Basel). 2019 Jan 14;11(1). pii: E90. doi: 10.3390/cancers11010090. Review.

10.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E.

EBioMedicine. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20.

11.

Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.

Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG.

Eur J Cancer. 2019 Jan;106:225-233. doi: 10.1016/j.ejca.2018.10.024. Epub 2018 Dec 5.

PMID:
30528807
12.

Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide.

Tassinari M, Cimino-Reale G, Nadai M, Doria F, Butovskaya E, Recagni M, Freccero M, Zaffaroni N, Richter SN, Folini M.

J Med Chem. 2018 Oct 11;61(19):8625-8638. doi: 10.1021/acs.jmedchem.8b00502. Epub 2018 Sep 20.

PMID:
30188709
13.

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

Raccagni I, Belloli S, Valtorta S, Stefano A, Presotto L, Pascali C, Bogni A, Tortoreto M, Zaffaroni N, Daidone MG, Russo G, Bombardieri E, Moresco RM.

PLoS One. 2018 May 23;13(5):e0197754. doi: 10.1371/journal.pone.0197754. eCollection 2018.

14.

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy.

Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, Avuzzi B, Morlino S, Visentin ME, Zaffaroni N, Rancati T, Valdagni R.

Dis Markers. 2018 Feb 25;2018:9128128. doi: 10.1155/2018/9128128. eCollection 2018.

15.

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.

Pavlin M, Spinello A, Pennati M, Zaffaroni N, Gobbi S, Bisi A, Colombo G, Magistrato A.

Sci Rep. 2018 Jan 12;8(1):649. doi: 10.1038/s41598-017-17364-4.

16.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C.

Cancer Lett. 2018 Feb 28;415:187-197. doi: 10.1016/j.canlet.2017.12.009. Epub 2017 Dec 7.

PMID:
29225052
17.

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.

Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P.

Biochem Pharmacol. 2018 Jan;147:93-103. doi: 10.1016/j.bcp.2017.11.009. Epub 2017 Nov 16.

PMID:
29155058
18.

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.

Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, Togliardi E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Colecchia M, Busico A, Pennati M, Zaffaroni N, Mariani L, Salvioni R.

Urol Oncol. 2018 Jan;36(1):8.e1-8.e8. doi: 10.1016/j.urolonc.2017.08.020. Epub 2017 Sep 12.

PMID:
28911922
19.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.

Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, Lanzi C, Cassinelli G, Zappasodi R, Tripodo C, Gulino A, Zaffaroni N, Di Nicola M.

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21. No abstract available.

PMID:
28730742
20.

miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.

Cimino-Reale G, Gandellini P, Santambrogio F, Recagni M, Zaffaroni N, Folini M.

J Hematol Oncol. 2017 Jul 17;10(1):140. doi: 10.1186/s13045-017-0510-3.

21.

Eleven-year management of prostate cancer patients on active surveillance: what have we learned?

Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, Biasoni D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoin E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, Valdagni R.

Tumori. 2017 Sep 18;103(5):464-474. doi: 10.5301/tj.5000649. Epub 2017 Jun 14.

22.

Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.

Corno C, Gatti L, Arrighetti N, Carenini N, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2017 Jul 15;136:40-50. doi: 10.1016/j.bcp.2017.04.002. Epub 2017 Apr 9.

PMID:
28404378
23.

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.

Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, Busico A, Colecchia M, Nicolai N, Mariani L, Salvioni R.

Ann Oncol. 2017 Jun 1;28(6):1346-1351. doi: 10.1093/annonc/mdx124.

PMID:
28383677
24.

microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies.

Gandellini P, Doldi V, Zaffaroni N.

Semin Cancer Biol. 2017 Jun;44:132-140. doi: 10.1016/j.semcancer.2017.03.005. Epub 2017 Mar 23. Review.

PMID:
28344166
25.

Synthesis and Superpotent Anticancer Activity of Tubulysins Carrying Non-hydrolysable N-Substituents on Tubuvaline.

Sani M, Lazzari P, Folini M, Spiga M, Zuco V, De Cesare M, Manca I, Dall'Angelo S, Frigerio M, Usai I, Testa A, Zaffaroni N, Zanda M.

Chemistry. 2017 Apr 27;23(24):5842-5850. doi: 10.1002/chem.201700874. Epub 2017 Apr 12.

PMID:
28300330
26.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
27.

miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.

El Bezawy R, Cominetti D, Fenderico N, Zuco V, Beretta GL, Dugo M, Arrighetti N, Stucchi C, Rancati T, Valdagni R, Zaffaroni N, Gandellini P.

Cancer Lett. 2017 Jun 1;395:53-62. doi: 10.1016/j.canlet.2017.02.033. Epub 2017 Mar 6.

PMID:
28274892
28.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.

J Med Chem. 2017 Apr 13;60(7):3082-3093. doi: 10.1021/acs.jmedchem.7b00105. Epub 2017 Mar 20.

PMID:
28272894
29.

Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.

Lanzi C, Zaffaroni N, Cassinelli G.

Curr Med Chem. 2017;24(26):2860-2886. doi: 10.2174/0929867324666170216114248. Review.

PMID:
28215163
30.

Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads.

D'Annessa I, Sattin S, Tao J, Pennati M, Sànchez-Martìn C, Moroni E, Rasola A, Zaffaroni N, Agard DA, Bernardi A, Colombo G.

Chemistry. 2017 Apr 19;23(22):5188-5192. doi: 10.1002/chem.201700169. Epub 2017 Mar 22.

31.

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.

El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, Zaffaroni N.

J Hematol Oncol. 2017 Jan 18;10(1):19. doi: 10.1186/s13045-016-0387-6.

32.

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016.

33.

The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.

Cassinelli G, Zaffaroni N, Lanzi C.

Cancer Lett. 2016 Nov 28;382(2):245-254. doi: 10.1016/j.canlet.2016.09.004. Epub 2016 Sep 22. Review.

PMID:
27666777
34.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

35.

[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors.

Spanò V, Pennati M, Parrino B, Carbone A, Montalbano A, Lopergolo A, Zuco V, Cominetti D, Diana P, Cirrincione G, Zaffaroni N, Barraja P.

Eur J Med Chem. 2016 Nov 29;124:840-851. doi: 10.1016/j.ejmech.2016.09.013. Epub 2016 Sep 5.

PMID:
27643641
36.

Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.

Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S.

J Clin Endocrinol Metab. 2016 Dec;101(12):4594-4602. Epub 2016 Sep 14.

37.

Emerging Role of G-quadruplex DNA as Target in Anticancer Therapy.

Cimino-Reale G, Zaffaroni N, Folini M.

Curr Pharm Des. 2016;22(44):6612-6624. doi: 10.2174/1381612822666160831101031. Review.

PMID:
27587203
38.

PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.

Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L.

Toxicol Appl Pharmacol. 2016 Nov 1;310:9-19. doi: 10.1016/j.taap.2016.08.005. Epub 2016 Aug 20.

PMID:
27554045
39.

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.

Spanò V, Pennati M, Parrino B, Carbone A, Montalbano A, Cilibrasi V, Zuco V, Lopergolo A, Cominetti D, Diana P, Cirrincione G, Barraja P, Zaffaroni N.

J Med Chem. 2016 Aug 11;59(15):7223-38. doi: 10.1021/acs.jmedchem.6b00777. Epub 2016 Jul 26.

PMID:
27428868
40.

Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.

Gasparini P, Casanova M, Villa R, Collini P, Alaggio R, Zin A, Bonvini P, Antonescu CR, Boldrini R, Caserini R, Moro M, Centonze G, Meazza C, Massimino M, Bergamaschi L, Luksch R, Chiaravalli S, Bisogno G, Zaffaroni N, Daidone MG, Sozzi G, Ferrari A.

Oncotarget. 2016 Sep 13;7(37):58903-58914. doi: 10.18632/oncotarget.10368.

41.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

42.

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.

Lopergolo A, Perrone R, Tortoreto M, Doria F, Beretta GL, Zuco V, Freccero M, Borrello MG, Lanzi C, Richter SN, Zaffaroni N, Folini M.

Oncotarget. 2016 Aug 2;7(31):49649-49663. doi: 10.18632/oncotarget.10105.

43.

Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt.

Costa B, Dangate M, Vetro M, Donvito G, Gabrielli L, Amigoni L, Cassinelli G, Lanzi C, Ceriani M, De Gioia L, Filippi G, Cipolla L, Zaffaroni N, Perego P, Colombo D.

Bioorg Med Chem. 2016 Aug 15;24(16):3396-405. doi: 10.1016/j.bmc.2016.05.031. Epub 2016 May 18.

PMID:
27316541
44.

Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements.

Salerno D, Beretta GL, Zanchetta G, Brioschi S, Cristofalo M, Missana N, Nardo L, Cassina V, Tempestini A, Giovannoni R, Cerrito MG, Zaffaroni N, Bellini T, Mantegazza F.

Biophys J. 2016 May 24;110(10):2151-61. doi: 10.1016/j.bpj.2016.02.030.

45.

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.

Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P.

Curr Med Chem. 2016;23(15):1496-512. Review.

PMID:
27048336
46.

Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.

Doldi V, Pennati M, Forte B, Gandellini P, Zaffaroni N.

Cell Mol Life Sci. 2016 Jul;73(13):2531-42. doi: 10.1007/s00018-016-2176-3. Epub 2016 Mar 12. Review.

PMID:
26970978
47.

TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site.

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, Bürdek M, Botti L, Arioli I, Cova A, Mauri G, Vergani E, Bianchi B, Della Mina P, Cantone L, Bollati V, Zaffaroni N, Gianni AM, Colombo MP, Huber V.

Clin Cancer Res. 2016 Jul 15;22(14):3499-512. doi: 10.1158/1078-0432.CCR-15-2170. Epub 2016 Mar 4.

48.

miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.

Crippa E, Folini M, Pennati M, Zaffaroni N, Pierotti MA, Gariboldi M.

Oncotarget. 2016 Apr 5;7(14):18594-604. doi: 10.18632/oncotarget.7617.

49.

Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent: a patent evaluation of WO2015048365 (A1).

Beretta GL, Zaffaroni N, Varchi G.

Expert Opin Ther Pat. 2016 May;26(5):637-42. doi: 10.1517/13543776.2016.1146692. Epub 2016 Feb 15.

PMID:
26814056
50.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.

De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N.

J Transl Med. 2016 Jan 25;14:25. doi: 10.1186/s12967-016-0781-4.

Supplemental Content

Loading ...
Support Center